VEGFA and renal cell adenocarcinoma: Our findings were consistent with those of the pembrolizumab plus axitinib trial in renal cell cancer.25 However, the combinations of PD-1/PD-L1 and VEGF pathway inhibitors did report unacceptable toxicities in some studies.26